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ABSTRACT
Only 10% to 20% of pancreatic tumors are resectable at
the time of diagnosis. Patients with advanced disease
have a median survival of 4.9 months. Palliation is often
required for biliary or duodenal obstruction, or both, and
for pain. Optimal palliation should guarantee the short-
est possible hospital stay and as long a survival as possi-
ble with a good quality of life. In recent years, treatment
options for palliation of biliary and duodenal obstruction
due to pancreatic cancer have broadened. Endoscopic
and percutaneous biliary stenting have been shown to be
successful tools for safe palliation of high-risk patients.
Nevertheless, fit patients with unresectable pancreatic
cancer benefit from surgery, which allows long-lasting
biliary and gastric drainage.
While laparoscopic cholecystojejunostomy and gastroen-
terostomy in patients with advanced pancreatic cancer
have been widely reported, laparoscopic hepatico-
jejunostomy has been rarely described. In this article, we
describe our technique of laparoscopic hepatico-jejunos-
tomy and gastrojejunostomy. We also discuss current evi-
dence on the indications for these procedures in patients
with unresectable pancreatic cancer. 
Key Words: Laparoscopy, Hepatico-jejunostomy,
Gastroenterostomy, Pancreatic cancer.
INTRODUCTION
The treatment of pancreatic carcinoma is almost entirely
palliative. Only 10% to 20% of tumors are resectable at
the time of diagnosis, and even in these patients, survival
beyond 5 years can be anticipated in no more than 10%.1
The median survival of patients with advanced disease is
4.9 months.2 These data underscore the importance of an
optimal palliation that will guarantee the shortest possi-
ble hospital stay and as long a survival as possible with
a good quality of life.
Obstructive jaundice is the most common symptom
requiring palliation, occurring in 70% of patients.
Duodenal obstruction, occurring in 10% to 25% of
patients, is rarely a presenting symptom (< 5%) and usu-
ally follows biliary obstruction.
The palliative treatment of carcinoma of the pancreas is
difficult. Careful evaluation of the patient and multidisci-
plinary expertise are required to select the appropriate
approach. Several risk factors are usually present: more
than 50% of patients are over the age of 70 years, and
they often have associated medical illnesses.3 Jaundice
and poor nutritional status can further compound the
problems associated with the operative treatment.
Although the mortality for palliative operations has
recently improved, morbidity rates have remained high.4
Decision making in the palliation of jaundice and duo-
denal obstruction due to pancreatic cancer has become
more complex in recent years. Treatment options have
broadened with the advent of endoscopic and percuta-
neous stenting of the bile ducts and laparoscopic biliary
and enteric bypass.
The availability of these minimally invasive techniques
has also increased the demand for accurate staging.
Resectability of pancreatic lesions is determined accu-
rately by preoperative imaging in only 47% to 55% of
cases.5 Diagnostic laparoscopy and laparoscopic ultra-
sonography are indicated in patients whose tumor is
deemed resectable on preoperative imaging.6 Using
laparoscopy and laparoscopic sonography, the
resectability rate can be determined correctly in 75% to
100% of patients.7 In other words, 33% to 65% of patients
can be spared a negative laparotomy for unresectable
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disease.7 False-positive results, ie, resectable lesions
judged unresectable by staging laparoscopy, have not
occurred in any of the prospectively reported controlled
studies.6-8 For these reasons, a laparoscopic approach to
the palliation of advanced pancreatic cancer based on the
findings of staging laparoscopy and laparoscopic ultra-
sonography may have the potential to replace open
bypass procedures.
In this article, we describe the surgical technique for
laparoscopic hepatico- and gastrojejunostomy and dis-
cuss the indications for these procedures in patients with
advanced pancreatic cancer.
SURGICAL TECHNIQUE 
Although laparoscopic cholecystojejunostomy has been
reported by many authors,9-14 few have described laparo-
scopic hepatico-jejunostomy for the palliation of
advanced pancreatic cancer.15,16 Laparoscopic hepatico-
jejunostomy is a difficult procedure, requiring expertise
in advanced laparoscopy. Palliation of duodenal obstruc-
tion by laparoscopic gastrojejunostomy has also been
widely described.17-19
When dealing with tumors deemed resectable on preoper-
ative imaging, a complete laparoscopic evaluation of
resectability, which includes laparoscopic ultrasonography,
is performed. First, the liver is examined. The probe is
positioned on the ventral surface of the liver with gentle
pressure. The entire hepatic tissue is carefully searched for
secondary lesions. The extrahepatic bile ducts and the ves-
sels of the hepatoduodenal ligament are then scanned.
Involvement of lymph nodes, the hepatic artery, and por-
tal vein are noted. This is a crucial step of the intraopera-
tive assessment of resectability. The presence or absence of
tumor invasion into the major vessels, especially the portal
vein, must be ruled out. Using the stomach as an acoustic
window, the pancreas is then examined (Figure 1). The
size and location of the tumor may be documented at this
point of the procedure. Involvement of the mesenteric
vessels and the celiac trunk is ruled out. The gastrocolic
ligament is then opened with the Harmonic scalpel
(Ethicon Endo-Surgery, Cincinnati, OH) and access to the
anterior surface of the pancreas is achieved (Figure 2).
The pancreatic lesion is usually identified, either by
laparoscopy (Figure 2) or by laparoscopic ultrasonogra-
phy (Figure 3). 
Once the lesion is judged unresectable, and in the pres-
ence of an indication for palliation, laparoscopic side-to-
side hepatico- and gastrojejunostomy, using a simple
jejunal loop, are performed. 
An antecolic gastrojejunostomy is preferred because it
lessens the possibility of subsequent infiltration by a
tumor. A small opening is made both into the posterior
wall of the stomach and the jejunal loop with the
Harmonic scalpel (Figure 4). The jaws of an Endo-GIA
stapler (3.5 mm/30 mm, US Surgical, Norwalk, CT) are
inserted into the enterotomies and a wide gastrojejunos-
tomy is created by 3 firings of the stapler (Figure 5). The
staple line is carefully inspected for bleeding and the
enterotomies are closed with a running suture (Figures
6 and 7).
Figure 1. Using the stomach as an acoustic window, the pan-
creas is examined by laparoscopic ultrasonogrphy.
Figure 2. The gastrocolic ligament is opened and the probe is
placed directly on the anterior surface of the pancreas.JSLS(2002)6:331-338 333
The hepatoduodenal ligament is further dissected, and the
common bile duct, cystic duct, and cystic artery are isolat-
ed. The cystic duct and the cystic artery are divided, and
cholecystectomy is performed. The gallbladder is removed
to facilitate construction of the common hepatic duct anas-
tomosis and to prevent the possible later complication of
cystic duct obstruction and cholecystitis. An incision of
approximately 1 cm is performed on the common hepat-
ic duct (Figure 8). If present, a hepatic duct drain is
removed under direct vision (Figure 9). Using the same
loop of jejunum that was selected for the gastrojejunosto-
my, a hepatico-jejunostomy is performed distal to the gas-
trojejunostomy. Two stay sutures are applied to fix the
loop of jejunum to the common hepatic duct. A small
enterotomy is performed on the intestinal wall. The jaws
Figure 3. The tumor is identified.
Figure 4. A small opening is made into the posterior wall of the
stomach and the jejunal loop.
Figure 5. The jaws of an Endo-GIA are inserted into the entero-
tomies.
Figure 6. The staple line is inspected for bleeding.
of an Endo-GIA stapler (3.5 mm/30 mm, US Surgical,
Norwalk, CT) are inserted into the common hepatic duct
and the jejunal loop (Figure 10). Using a single firing of
the stapler, the side-to-side anastomosis is created (Figure
11). The 2 openings are then closed with a running suture
(Figure 12). A drain is left in situ.
DISCUSSION
Optimal palliation should alleviate symptoms effectively,
thereby improving the quality of life while reducing the
duration of hospital stay. Palliation of patients with unre-
sectable pancreatic cancer is aimed at 3 major symptoms:
obstructive jaundice, duodenal/gastric outlet obstruction,
and tumor-associated pain.Palliative Laparoscopic Hepatico- and Gastrojejunostomy for Advanced Pancreatic Cancer, Gentileschi P et al.
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In a review of 8,000 patients in the English literature from
1965 to 1980,20 the relief of biliary obstruction with sur-
gical biliary bypass was associated with longer and more
comfortable survival (5.4 months) when compared with
diagnostic laparotomy alone (3.5 months). For these rea-
sons, an attempt to palliate biliary obstruction is indicat-
ed in all but the most terminal patients.
Open palliative surgery has been associated with high
mortality and morbidity rates (8% to 33% and 20% to 60%,
respectively).4,11 The introduction of endoscopic and per-
cutaneous stenting of the bile ducts has changed the
management of these patients. Several randomized stud-
ies compared biliary stenting with open bypass proce-
dures.21-23 Morbidity, mortality, and primary hospital stay
were found to be lower after stenting. In particular, a ran-
domized comparative trial (surgical vs. endoscopic palli-
ation of jaundice) was conducted at the Middlesex
Hospital in London.24 In the study, 204 patients were ran-
domized to either surgery (n = 103) or endoscopic stent
placement (n = 101). Technical success was achieved in
94% and 95% of surgical and stent patients, respectively.
Stented patients experienced lower procedure-related
mortality (3% vs. 14%; P = 0.01), major complication rate
(11% vs. 29%; P = 0.02), and median total hospital stay
(20 vs. 26 days; P = 0.001). However, recurrent jaundice
occurred in 36 stented patients and only 2 surgical
patients. Median survival was similar in the 2 groups
Figure 7. The enterotomies are closed with a running suture.
Figure 8. A small incision is performed on the common hepatic
duct.
Figure 9. An eventual hepatic duct drain is removed under visu-
alization.
Figure 10. Insertion of the jaws of an Endo-GIA stapler into the
hepatic duct and jejunum.(surgical = 26 weeks, stent = 21 weeks; P = 0.065). The
authors concluded that endoscopic stenting is easier and
safer, but surgical bypass provides more durable relief of
jaundice. The endoscopic approach, also when com-
pared with percutaneous stenting, demonstrated signifi-
cantly higher success rates and lower mortality.25 As for
unilateral versus bilateral endoscopic hepatic duct
drainage in patients with malignant biliary obstruction,
the results of a prospective, randomized study demon-
strated that the insertion of more than 1 endoprosthesis
is not routinely justified.26 Single stent insertion proved
to be effective, while avoiding the risk of further proce-
dure-related complications and mortality. The major dis-
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advantage of endoscopic stents is their short-life patency.
The recurrent jaundice rate ranges from 5% to 24%.27
These data suggest that fit jaundiced patients with unre-
sectable pancreatic cancer benefit from surgery, whereas
poor operative risk patients should be treated with endo-
scopic or percutaneous stenting.
Current opinion is divided regarding the preferred surgi-
cal procedure for biliary-enteric bypass. In an analysis of
600 patients who underwent open biliary bypass in 8
reported series,28 93 of 400 patients (23%) developed
recurrent jaundice after cholecystojejunostomy compared
with 14 of 200 patients (7%) after hepatico-jejunostomy.
In a prospective controlled trial assessing the efficacy of
biliary enteric bypass,29 31 patients were randomized to
cholecystojejunostomy and hepatico-jejunostomy. Seven
bypasses failed after use of the gallbladder and only 2
after using the bile duct (P < 0.04). Prior to death, 47%
of cholecystojejunostomies failed. The authors concluded
that hepatico-jejunostomy is a significantly more effective
palliative procedure. A meta-analysis by Watanapa and
Williamson30 found that cholecystojejunostomy had an
89% success rate, whereas the success rate for hepatico-
jejunostomy was 97%. More importantly, recurrent jaun-
dice or cholangitis occurred in 20% of patients undergo-
ing cholecystojejunostomy. On the basis of these data,
most authors have preferred the routine use of the com-
mon bile duct for palliative biliary drainage.
The issue of duodenal obstruction, its management, and
treatment in patients with advanced pancreatic cancer
has been addressed by 3 meta-analyses.20,30,31 Sarr and
Cameron20 reviewed more than 8000 surgically managed
patients with unresectable pancreatic cancer. Thirteen
percent of those who did not undergo a bypass proce-
dure at their initial operation required gastrojejunostomy
prior to death, and an additional 20% died with symp-
toms of duodenal obstruction. Another meta-analysis30
included 1600 patients and reported a 17% incidence of
duodenal obstruction at a mean of 8.6 months after the
initial operation, requiring gastrojejunostomy before
death. Singh and Reber31 analyzed 950 patients with
advanced pancreatic cancer. Twenty-one percent
required late gastrojejunostomy. In all analyses, the addi-
tion of gastrojejunostomy at the initial operation did not
increase operative mortality. Conversely, when gastroje-
junostomy was performed as a second operation, the
mortality rates approached 25%.
Figure 11. Firing the stapler, a side-to-side hepatico-jejunostomy
is created.
Figure 12. The 2 openings are closed with a running suture. Palliative Laparoscopic Hepatico- and Gastrojejunostomy for Advanced Pancreatic Cancer, Gentileschi P et al.
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Despite these data, controversy still exists over the role of
prophylactic gastrojejunostomy in these patients. Espat
and colleagues32 analyzed 155 laparoscopically staged
patients with unresectable pancreatic carcinoma. They
received no biliary and gastric bypass procedures and
were prospectively followed to determine the frequency
of subsequent gastric or biliary bypass, or both, required
prior to death. The study revealed that 98% (152 of 155)
of these patients did not require a subsequent procedure
to treat biliary or gastric obstruction. However, 35% of
patients in this study had tumors in the body and tail of
the pancreas, which represents a group with differing
needs for palliation. In a recent, prospective, randomized
trial, the need of prophylactic gastrojejunostomy in
advanced pancreatic cancer was evaluated.33 Eighty-
seven patients with no evidence of duodenal obstruction
were randomized to receive either a gastrojejunostomy
(44 patients) or no gastrojejunostomy (43 patients).
Gastrojejunostomy did not influence morbidity, mortality,
and length of hospital stay. No patients experienced late
gastric outlet obstruction in the gastrojejunostomy group,
whereas 19% of patients in the no-gastrojejunostomy
group required bypass for gastric outlet obstruction (P <
0.01). This study provided class I evidence confirming the
need for routine gastrojejunostomy in surgically explored
patients with unresectable pancreatic cancer.
The use of minimally invasive operative techniques has
been applied to the management of pancreatic cancer. The
role of diagnostic laparoscopy and laparoscopic ultra-
sonography for the intraoperative staging of pancreatic car-
cinoma has been well established and is the routine at
advanced centers.7 To date, many reports have described
the use of laparoscopic techniques for palliation of patients
with advanced pancreatic cancer.9-19 These include laparo-
scopic hepatico-jejunostomy, cholecystojejunostomy, and
gastrojejunostomy. Initial results demonstrate technical
success, with acceptable morbidity and mortality and
encouraging outcomes. In a case-controlled study, laparo-
scopic gastroenterostomy and end-to-side hepatico-
jejunostomy (Roux-en-Y) were performed in 14 unre-
sectable patients.15 The results were compared with those
of 14 matched patients who had conventional palliative
procedures. Postoperative morbidity was 7% and 43% for
laparoscopic and open palliation, respectively (P < 0.05).
No deaths occurred in the laparoscopic group, compared
to 29% in the open group (P < 0.05). Mean postoperative
hospital stay was 9 days in the laparoscopic group and 21
days in the open group (P < 0.06). Morphine derivatives
were necessary for a significantly shorter period following
laparoscopic palliation (P < 0.03). These results strongly
support the use of a laparoscopic approach to palliation of
advanced pancreatic cancer. Reduced pain and early rein-
stitution of normal bowel motility after laparoscopy may
contribute to the lower incidence of cardiopulmonary
complications leading to postoperative deaths in these
high-risk patients.
Another study compared the short-term outcomes of
open gastrojejunostomy (22 patients) to laparoscopic
gastrojejunostomy (9 diagnosis-matched controls) for the
palliation of gastric outlet obstruction caused by
advanced pancreatic cancer.18 Mortality, overall morbidi-
ty, operating time, time to oral solid food intake, nons-
teroidal antiinflammatory drug consumption, opioid con-
sumption, and survival were not significantly different
between the 2 groups. Estimated blood loss and hospital
stay were significantly reduced in the laparoscopic group
(P < 0.01 and P < 0.05, respectively). Delayed gastric
emptying had played a major role in prolonged hospital
stay after open palliation, being found in 12% to 67% of
cases.27 After laparoscopic palliative procedures, this
complication has only rarely been reported.
Further clinical trials will be needed to demonstrate an
evidence-based advantage of the laparoscopic approach
to palliation of patients with advanced pancreatic cancer.
To date, in patients deemed resectable on preoperative
imaging, a diagnostic laparoscopic approach seems rea-
sonable. Furthermore, with laparoscopic ultrasonogra-
phy, intraoperative staging can be extremely accurate.6,7
Unresectable patients may be further palliated by opera-
tive laparoscopic bypass. The technique described in this
article for laparoscopic double bypass is technically chal-
lenging but has the potential to allow for a minimally
invasive and durable biliary and gastric drainage.
Currently, the laparoscopic approach for palliation of
advanced pancreatic cancer is commonly used in
advanced minimally invasive centers. Fit patients can be
spared an unnecessary laparotomy while receiving long-
lasting biliary or gastric drainage, or both, through a sur-
gical stoma. Whether this minimally invasive approach
will be extended to a larger number of centers and
patients is yet to be determined.References:
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